XML 41 R30.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Collaboration and Licensing Revenue (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summarized Collaboration and Licensing Revenues | The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and six months ended June 30, 2017 and 2016.
| Three Months Ended June 30, 2017
| Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 4,842 |  |  | $ | 5,122 |  |  | $ | 9,964 |
Oragenics, Inc. | 261 |  |  | 214 |  |  | 475 |
Fibrocell Science, Inc. | 605 |  |  | 1,348 |  |  | 1,953 |
Genopaver, LLC | 68 |  |  | 1,445 |  |  | 1,513 |
S & I Ophthalmic, LLC | — |  |  | 72 |  |  | 72 |
OvaXon, LLC | — |  |  | 880 |  |  | 880 |
Intrexon Energy Partners, LLC | 625 |  |  | 1,295 |  |  | 1,920 |
Persea Bio, LLC | 125 |  |  | 141 |  |  | 266 |
Ares Trading S.A. | 1,597 |  |  | 1,206 |  |  | 2,803 |
Intrexon Energy Partners II, LLC | 500 |  |  | 456 |  |  | 956 |
Intrexon T1D Partners, LLC | 272 |  |  | 1,016 |  |  | 1,288 |
Harvest start-up entities (1) | 606 |  |  | 3,846 |  |  | 4,452 |
Other | 923 |  |  | 699 |  |  | 1,622 |
Total | $ | 10,424 |  |  | $ | 17,740 |  |  | $ | 28,164 |
(1) | For the three months ended June 30, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
| Three Months Ended June 30, 2016
| Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 922 |  |  | $ | 6,048 |  |  | $ | 6,970 |
Oragenics, Inc. | 261 |  |  | 246 |  |  | 507 |
Fibrocell Science, Inc. | 605 |  |  | 789 |  |  | 1,394 |
Genopaver, LLC | 68 |  |  | 1,569 |  |  | 1,637 |
S & I Ophthalmic, LLC | — |  |  | 2,358 |  |  | 2,358 |
OvaXon, LLC | — |  |  | 808 |  |  | 808 |
Intrexon Energy Partners, LLC | 625 |  |  | 3,587 |  |  | 4,212 |
Persea Bio, LLC | 125 |  |  | 206 |  |  | 331 |
Ares Trading S.A. | 1,597 |  |  | 621 |  |  | 2,218 |
Intrexon Energy Partners II, LLC | 500 |  |  | 394 |  |  | 894 |
Intrexon T1D Partners, LLC | 278 |  |  | 32 |  |  | 310 |
Harvest start-up entities (1) | 305 |  |  | 634 |  |  | 939 |
Other | 2,769 |  |  | 2,134 |  |  | 4,903 |
Total | $ | 8,055 |  |  | $ | 19,426 |  |  | $ | 27,481 |
(1) | For the three months ended June 30, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and Relieve Genetics, Inc.
| Six Months Ended June 30, 2017
| Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 9,684 |  |  | $ | 11,265 |  |  | $ | 20,949 |
Oragenics, Inc. | 524 |  |  | 520 |  |  | 1,044 |
Fibrocell Science, Inc. | 1,210 |  |  | 2,482 |  |  | 3,692 |
Genopaver, LLC | 137 |  |  | 3,056 |  |  | 3,193 |
S & I Ophthalmic, LLC | — |  |  | 375 |  |  | 375 |
OvaXon, LLC | — |  |  | 1,704 |  |  | 1,704 |
Intrexon Energy Partners, LLC | 1,250 |  |  | 5,756 |  |  | 7,006 |
Persea Bio, LLC | 250 |  |  | 305 |  |  | 555 |
Ares Trading S.A. | 3,194 |  |  | 2,924 |  |  | 6,118 |
Intrexon Energy Partners II, LLC | 1,000 |  |  | 1,105 |  |  | 2,105 |
Intrexon T1D Partners, LLC | 536 |  |  | 1,884 |  |  | 2,420 |
Harvest start-up entities (1) | 1,207 |  |  | 6,608 |  |  | 7,815 |
Other | 2,756 |  |  | 1,497 |  |  | 4,253 |
Total | $ | 21,748 |  |  | $ | 39,481 |  |  | $ | 61,229 |
(1) | For the six months ended June 30, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
| Six Months Ended June 30, 2016
| Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 1,844 |  |  | $ | 12,107 |  |  | $ | 13,951 |
Oragenics, Inc. | 524 |  |  | 789 |  |  | 1,313 |
Fibrocell Science, Inc. | 1,210 |  |  | 2,041 |  |  | 3,251 |
Genopaver, LLC | 137 |  |  | 3,078 |  |  | 3,215 |
S & I Ophthalmic, LLC | — |  |  | 3,544 |  |  | 3,544 |
OvaXon, LLC | — |  |  | 1,502 |  |  | 1,502 |
Intrexon Energy Partners, LLC | 1,250 |  |  | 6,950 |  |  | 8,200 |
Persea Bio, LLC | 250 |  |  | 405 |  |  | 655 |
Ares Trading S.A. | 3,194 |  |  | 1,429 |  |  | 4,623 |
Intrexon Energy Partners II, LLC | 1,000 |  |  | 444 |  |  | 1,444 |
Intrexon T1D Partners, LLC | 278 |  |  | 32 |  |  | 310 |
Harvest start-up entities (1) | 351 |  |  | 1,022 |  |  | 1,373 |
Other | 3,789 |  |  | 4,384 |  |  | 8,173 |
Total | $ | 13,827 |  |  | $ | 37,727 |  |  | $ | 51,554 |
(1) | For the six months ended June 30, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and Relieve Genetics, Inc.
Summary of Deferred Revenue | Deferred revenue consists of the following:
| June 30, 2017 |  | December 31, 2016
Upfront and milestone payments | $ | 278,262 |  |  | $ | 297,867 |
Prepaid research and development services | 2,502 |  |  | 6,015 |
Prepaid product and service revenues | 4,550 |  |  | 5,554 |
Other | 4 |  |  | 706 |
Total | $ | 285,318 |  |  | $ | 310,142 |
Current portion of deferred revenue | $ | 47,662 |  |  | $ | 53,364 |
Long-term portion of deferred revenue | 237,656 |  |  | 256,778 |
Total | $ | 285,318 |  |  | $ | 310,142 |
Summary of Deferred Revenue by Collaborator | The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement.
| June 30, 2017 |  | December 31, 2016
ZIOPHARM Oncology, Inc. | $ | 129,125 |  |  | $ | 138,809 |
Oragenics, Inc. | 7,242 |  |  | 7,766 |
Fibrocell Science, Inc. | 17,816 |  |  | 19,026 |
Genopaver, LLC | 1,840 |  |  | 1,977 |
Intrexon Energy Partners, LLC | 16,875 |  |  | 18,125 |
Persea Bio, LLC | 3,750 |  |  | 4,000 |
Ares Trading S.A. | 43,984 |  |  | 47,178 |
Intrexon Energy Partners II, LLC | 14,833 |  |  | 15,833 |
Intrexon T1D Partners, LLC | 8,678 |  |  | 8,653 |
Harvest start-up entities (1) | 19,400 |  |  | 20,208 |
Other | 14,719 |  |  | 16,292 |
Total | $ | 278,262 |  |  | $ | 297,867 |
(1) | As of June 30, 2017 and December 31, 2016, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.

X
- Definition Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765 + Details
Name: | us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of summarized revenues recognized for each significant collaboration and licensing agreement and aggregated nonsignificant collaborations and licensing agreements. + References No definition available. + Details
Name: | xon_CollaborationandLicensingRevenueTableTextBlock
Namespace Prefix: | xon_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts that comprise the deferred revenue by collaborator as of the balance sheet date. + References No definition available. + Details
Name: | xon_DeferredRevenueByCollaboratorDisclosureTableTextBlockTableTextBlock
Namespace Prefix: | xon_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration